NOVEL FOOD and PARNUTS Approval Granted for NKO Opens the 2nd Largest Nutraceutical Market for Neptune
NKO's strong clinically proven benefits for cardiovascular health will now lead Neptune's further expansion in the European omega-3 market, which is currently dominated by cardiovascular health applications with 80% of all omega-3 fatty acids targeting heart benefits.
20/02/09 Neptune Technologies & Bioressources Inc. has announced that the European Food Safety Association (EFSA) has approved Neptune Krill Oil (NKO) as a NOVEL FOOD and PARNUTS for commercialization in the European Union.
NKO has successfully passed rigorous regulatory review and scrutiny by all member states of the European Union (EU), which approved NKO as a NOVEL FOOD and PARNUTS allowing its immediate commercialization at a clinically proven effective daily dose in all 27 European countries.
NOVEL FOOD opens the European market to NKO for:
- Dietary Supplements
- Functional Foods
PARNUTS approval allows the commercialization of NKO as:
- Diet Meal Replacements
- Dietary Foods for Special Medical Purposes
"NKO's strong clinically proven benefits for cardiovascular health will now lead Neptune's further expansion in the European omega-3 market, which is currently dominated by cardiovascular health applications with 80% of all omega-3 fatty acids targeting heart benefits," stated Dr. Toni Rinow, Corporate Development and Investor Relations of Neptune. "According to market studies, the EU market is growing annually by 24 % and is expected to be worth $1.6 billion by 2014," she added.
"According to EFSA regulations, functional food and dietary supplements can only be commercialized at the daily dose established as safe, which is not always necessarily the effective dose. Fortunately, the daily dose accepted by EFSA as safe for NKO is also the one proven to be effective in all clinical studies with NKO," stated Dr. Tina Sampalis, Chief Scientific Officer of Neptune. "This opens the door for NKO to gain a leadership position in both dietary supplements and functional food markets, achieving targets unmet by other omega-3 products and krill competition," she added.
"Moreover, the NKO PARNUTS approval, which allows the commercialization of NKO for the dietary management of specific diseases, is expected to lead Neptune and its subsidiaries to major pharmaceutical opportunities," she concluded.
Neptune has already built substantial marketing visibility and recognition in Europe through its longstanding annual presence at Vitafoods International, the Global Nutraceutical Event, in Geneva, Switzerland, and Health and Food Ingredients in Paris, France. Based on these continuing marketing efforts, the proprietary status of its ingredients and the Novel Food approval, Neptune expects to accelerate market penetration and increase its market share of the omega-3 health ingredient market.
